MARKET

LXRX

LXRX

Lexicon PHARM
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.580
+0.050
+3.27%
After Hours: 1.580 0 0.00% 19:38 12/04 EST
OPEN
1.530
PREV CLOSE
1.530
HIGH
1.650
LOW
1.520
VOLUME
1.90M
TURNOVER
--
52 WEEK HIGH
5.33
52 WEEK LOW
1.030
MARKET CAP
185.61M
P/E (TTM)
-1.5065
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Look for Shares of Lexicon Pharmace to Potentially Pullback after Yesterday's 5.38% Rise
Lexicon Pharmace (NASDAQ:LXRX) traded in a range yesterday that spanned from a low of $1.56 to a high of $1.68. Yesterday, the shares gained 5.4%, which took the trading range above the 3-day high of $1.59 on volume of 13.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Comtex SmarTrend(R) · 11/25 17:32
The November Market Grinds Along
While it may not be my worst month this year, November may end up being the choppiest month for day trading I’ve traded so far in 2020.
Benzinga · 11/23 17:19
Mid-Afternoon Market Update: Nasdaq Turns Positive; Cinedigm Shares Slide
Toward the end of trading Tuesday, the Dow traded down 0.30% to 29,861.95 while the NASDAQ rose 0.21% to 11,948.77. The S&P also fell, dropping 0.12% to 3,622.50.
Benzinga · 11/17 19:46
Lexicon Pharmace Set to Possibly Pullback After Yesterday's Rally of 46.51%
Lexicon Pharmace (NASDAQ:LXRX) traded in a range yesterday that spanned from a low of $1.82 to a high of $2.38. Yesterday, the shares gained 46.5%, which took the trading range above the 3-day high of $1.31 on volume of 11.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Comtex SmarTrend(R) · 11/17 17:53
KNDI, RIOT, IBIO and GDRX among midday movers
Gainers: Phoenix Tree (DNK) +65%.Lexicon Pharmaceuticals (LXRX) +43%.Riot Blockchain (RIOT) +40%.Zomedica Pharmaceuticals (ZOM) +33%.Miragen Therapeutics (MGEN) +28%.AXT (AXTI) +27%.Glory Star New Media Group (GSMG) +26%.Yunhong CTI (CTIB) +23%.Kandi Technologies (KNDI) +22%.Sequential Brands (SQBG)
Seekingalpha · 11/17 17:44
Mid-Day Market Update: Sequential Brands Gains After Q3 Results; Brainstorm Cell Therapeutics Shares Plunge
Midway through trading Tuesday, the Dow traded down 0.45% to 29,814.37 while the NASDAQ fell 0.05% to 11,918.36. The S&P also fell, dropping 0.29% to 3,616.42.
Benzinga · 11/17 17:37
Lexicon Pharmaceuticals, Zomedica Pharmaceuticals leads healthcare gainers; Brainstorm Cell Therapeutics, GoodRx Holdings among losers
Gainers: Lexicon Pharmaceuticals (LXRX) +45%, Zomedica Pharmaceuticals (ZOM) +33%, Miragen Therapeutics (MGEN) +17%, SQZ Biotechnologies (SQZ) +15%, PLx Pharma (PLXP) +13%.Losers: Brainstorm Cell Therapeutics (BCLI) -67%, GoodRx Holdings (GDRX) -19%, iBio (IBIO) -18%, Co-Diagnostics (CODX) -17%, Alterity Therapeutics (ATHE) -16%.
Seekingalpha · 11/17 16:06
Why Lexicon Pharmaceuticals Stock Is Trading Higher Today
Lexicon Pharmaceuticals (NASDAQ: LXRX) shares are trading higher on Tuesday after the company's SOLOIST and SCORED Phase 3 studies achieved their primary endpoints.
Benzinga · 11/17 16:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LXRX. Analyze the recent business situations of Lexicon PHARM through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LXRX stock price target is 2.367 with a high estimate of 3.000 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 180
Institutional Holdings: 105.01M
% Owned: 89.39%
Shares Outstanding: 117.47M
TypeInstitutionsShares
Increased
29
3.64M
New
28
-1.21M
Decreased
25
5.39M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Independent Director
Raymond Debbane
President/Chief Executive Officer/Director
Lonnel Coats
Chief Financial Officer/Executive Vice President
Jeffrey Wade
Executive Vice President
Alan Main
Executive Vice President
Praveen Tyle
Vice President - Finance
James Tessmer
Vice President/General Counsel
Brian Crum
Independent Director
Philippe Amouyal
Independent Director
Samuel Barker
Independent Director
Robert Lefkowitz
Independent Director
Alan Nies
Independent Director
Frank Palantoni
Independent Director
Christopher Sobecki
Independent Director
Judith Swain
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About LXRX
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of treatments for human disease. The Company's drug programs include Sotagliflozin and LX9211. The Company also has a number of additional compounds into various stages of clinical and preclinical development. The Company’s LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company intends to initiate a Phase IIa clinical trial evaluating the safety and tolerability of LX9211 and its effects on diabetic peripheral neuropathic (DPN) pain. Its Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of type I diabetes and type II diabetes, heart failure and chronic kidney disease.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Lexicon Pharmaceuticals, Inc. stock information, including NASDAQ:LXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LXRX stock methods without spending real money on the virtual paper trading platform.